• Please log in or register to access this feature.

Editorial

You have full text access to this OnlineOpen article

Fructose takes a toll†‡

  1. Miriam B. Vos M.D., M.S.P.H.1,2,*,
  2. Craig J. McClain M.D.3,4,5,6

Article first published online: 5 AUG 2009

DOI: 10.1002/hep.23212

Issue

Hepatology

Hepatology

Volume 50, Issue 4, pages 1004–1006, October 2009

Additional Information

How to Cite

Vos, M. B. and McClain, C. J. (2009), Fructose takes a toll. Hepatology, 50: 1004–1006. doi: 10.1002/hep.23212

Author Information

  1. 1

    Department of Pediatrics, Emory University School of Medicine, Atlanta, GA

  2. 2

    Children's Healthcare of Atlanta, Atlanta, GA

  3. 3

    Department of Medicine, University of Louisville, Louisville, KY

  4. 4

    Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY

  5. 5

    Clinical and Translational Sciences Institute, University of Louisville, Louisville, KY

  6. 6

    Louisville VA Medical Center, Louisville, KY

*Department of Pediatrics, Emory University School of Medicine, 2015 Uppergate Drive Northeast, Atlanta, GA 30322

  1. †

    See Article on Page 1094.

  2. ‡

    Potential conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 28 SEP 2009
  2. Article first published online: 5 AUG 2009
  3. Accepted manuscript online: 5 AUG 2009 12:00AM EST

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (285K)

References

  • 1
    Havel PJ. Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. Nutr Rev 2005; 63: 133–157.
  • 2
    Vos MB, Kimmons JE, Gillespie C, Welsh J, Blanck HM. Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey. Medscape J Med 2008; 10: 160.
  • 3
    Thuy S, Ladurner R, Volynets V, Wagner S, Strahl S, Königsrainer A, et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 2008; 138: 1452–1455.
  • 4
    Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008; 48: 993–999.
  • 5
    Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. HEPATOLOGY 2009; 50: 1094–1104.
  • 6
    Rao SS, Attaluri A, Anderson L, Stumbo P. Ability of the normal human small intestine to absorb fructose: evaluation by breath testing. Clin Gastroenterol Hepatol 2007; 5: 959–963.
  • 7
    Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009; 119: 1322–1334.
  • 8
    Lê KA, Faeh D, Stettler R, Ith M, Kreis R, Vermathen P, et al. A 4-wk high-fructose diet alters lipid metabolism without affecting insulin sensitivity or ectopic lipids in healthy humans. Am J Clin Nutr 2006; 84: 1374–1379.
  • 9
    Vos MB, Weber MB, Welsh J, Khatoon F, Jones DP, Whitington PF, et al. Fructose and oxidized low-density lipoprotein in pediatric nonalcoholic fatty liver disease: a pilot study. Arch Pediatr Adolesc Med 2009; 163: 674–675.
  • 10
    Purohit V, Bode JC, Bode C, Brenner DA, Choudhry MA, Hamilton F, et al. Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical consequences: summary of a symposium. Alcohol 2008; 42: 349–361.
  • 11
    Kirpich IA, Solovieva NV, Leikhter SN, Shidakova NA, Lebedeva OV, Sidorov PI, et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 2008; 42: 675–682.
  • 12
    Uesugi T, Froh M, Arteel GE, Bradford BU, Thurman RG. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. HEPATOLOGY 2001; 34: 101–108.
  • 13
    Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 2009; 15: 1546–1558.
  • 14
    Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761–1772.
  • 15
    Ghoshal S, Witta J, Zhong J, de Villiers W, Eckhardt E. Chylomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res 2009; 50: 90–97.
  • 16
    Broitman SA, Gottlieb LS, Zamcheck N. Influence of neomycin and ingested endotoxin in the pathogenesis of choline deficiency cirrhosis in the adult rat. J Exp Med 1964; 119: 633–642.
  • 17
    Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance J Clin Invest 2006; 116: 3015–3025.
  • 18
    Zu L, He J, Jiang H, Xu C, Pu S, Xu G. Bacterial endotoxin stimulates adipose lipolysis via toll-like receptor 4 and extracellular signal-regulated kinase pathway. J Biol Chem 2009; 284: 5915–5926.
  • 19
    Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: endogenous danger signaling. Mol Med 2008; 14: 476–484.
  • 20
    Milanski M, Degasperi G, Coope A, Morari J, Denis R, Cintra DE, et al. Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: implications for the pathogenesis of obesity. J Neurosci 2009; 29: 359–370.
  • 21
    Zhao X-J, Dong Q, Bindas J, Piganelli JD, Magill A, Reiser J, et al. TRIF and IRF-3 binding to the TNF promoter results in macrophase TNF dysregulation and steatosis induced by chronic ethanol. J Immunol 2008; 181: 3049–3056.
View Full Article (HTML) Get PDF (285K)